Spinifex focuses on pain because it is an area of high unmet medical need. Demand for pain drugs continues to increase, fuelling the growth of a market that is expected to be worth US$50 billion annually by 2020. Neuropathic pain, where Spinifex is active, is estimated to affect 1.5 million patients worldwide and is currently poorly treated.

With a range of causes, neuropathic pain can be debilitating and a significant opportunity exists for new candidates that can deliver improved efficacy, side effect profile, time to onset and simplified dosing.